Mather Group LLC. Sells 247 Shares of Novo Nordisk A/S (NYSE:NVO)

Mather Group LLC. lessened its position in shares of Novo Nordisk A/S (NYSE:NVO) by 4.2% in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 5,588 shares of the company’s stock after selling 247 shares during the quarter. Mather Group LLC.’s holdings in Novo Nordisk A/S were worth $481,000 at the end of the most recent reporting period.

A number of other hedge funds also recently bought and sold shares of the company. Raymond James & Associates increased its position in Novo Nordisk A/S by 1.0% during the third quarter. Raymond James & Associates now owns 3,526,821 shares of the company’s stock valued at $419,939,000 after acquiring an additional 36,223 shares during the last quarter. Natixis Advisors LLC increased its position in Novo Nordisk A/S by 2.7% during the third quarter. Natixis Advisors LLC now owns 3,074,876 shares of the company’s stock valued at $366,125,000 after acquiring an additional 80,070 shares during the last quarter. International Assets Investment Management LLC increased its position in Novo Nordisk A/S by 10,608.4% during the third quarter. International Assets Investment Management LLC now owns 1,813,571 shares of the company’s stock valued at $215,942,000 after acquiring an additional 1,796,635 shares during the last quarter. LPL Financial LLC increased its position in Novo Nordisk A/S by 3.6% during the third quarter. LPL Financial LLC now owns 1,362,782 shares of the company’s stock valued at $162,266,000 after acquiring an additional 47,496 shares during the last quarter. Finally, DAVENPORT & Co LLC increased its position in Novo Nordisk A/S by 75.1% during the fourth quarter. DAVENPORT & Co LLC now owns 1,052,712 shares of the company’s stock valued at $90,477,000 after acquiring an additional 451,641 shares during the last quarter. Hedge funds and other institutional investors own 11.54% of the company’s stock.

Analyst Ratings Changes

A number of analysts recently commented on the company. Sanford C. Bernstein upgraded Novo Nordisk A/S from an “underperform” rating to a “market perform” rating in a research report on Monday, January 6th. BNP Paribas upgraded Novo Nordisk A/S to a “strong-buy” rating in a research report on Monday, December 2nd. BMO Capital Markets reduced their price target on Novo Nordisk A/S from $156.00 to $105.00 and set an “outperform” rating for the company in a research report on Monday, December 23rd. UBS Group upgraded Novo Nordisk A/S from a “sell” rating to a “buy” rating in a research report on Wednesday, January 8th. Finally, Cantor Fitzgerald restated an “overweight” rating and issued a $160.00 price target on shares of Novo Nordisk A/S in a research report on Wednesday, November 6th. One equities research analyst has rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Buy” and an average target price of $145.25.

Novo Nordisk A/S Stock Performance

NYSE NVO opened at $85.83 on Thursday. The firm has a market cap of $385.16 billion, a price-to-earnings ratio of 27.78, a price-to-earnings-growth ratio of 0.93 and a beta of 0.45. The company has a quick ratio of 0.75, a current ratio of 0.94 and a debt-to-equity ratio of 0.43. The business has a 50-day moving average price of $92.65 and a 200-day moving average price of $112.19. Novo Nordisk A/S has a twelve month low of $78.17 and a twelve month high of $148.15.

Novo Nordisk A/S (NYSE:NVO) last released its quarterly earnings data on Wednesday, February 5th. The company reported $0.91 earnings per share for the quarter, topping analysts’ consensus estimates of $0.88 by $0.03. Novo Nordisk A/S had a return on equity of 86.32% and a net margin of 35.03%. As a group, equities research analysts predict that Novo Nordisk A/S will post 3.16 EPS for the current fiscal year.

Novo Nordisk A/S Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.